Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck

By Pharmaceutical Processing | March 24, 2011

Portola Pharmaceuticals and Merck known as MSD outside the United States and Canada, today announced that Merck
plans to return to Portola all rights for betrixaban, an investigational oral
Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke
in patients with atrial fibrillation (SPAF). This decision was made following a
review of Merck’s investigational portfolio.

“Regaining full rights to betrixaban represents a
transformational opportunity for Portola,” said William Lis, chief
executive officer of Portola. “We will work with our academic partners on
options for an independent development plan to bring betrixaban to the market
and intend to discuss these options with the FDA in the near future.” In
July 2009, Merck and Portola announced an exclusive global collaboration and
license agreement for the development and commercialization of betrixaban.
Betrixaban most recently completed Phase II testing in the EXPLORE-Xa trial in
which it showed dose dependent clinical activity with similar or lower rates of
bleeding compared to warfarin in the study population. These results were presented
during a late-breaking clinical trials session at the American College
of Cardiology’s 59th Annual Scientific Session in March 2010.

“Working closely with our Portola collaborators we have
advanced betrixaban to this Phase III-ready stage,” said Luciano Rossetti,
M.D., senior vice president, Global Scientific Strategy at Merck. “As part
of an ongoing prioritization of our late-stage pipeline, we have decided to
return rights for betrixaban to Portola. Merck continues to advance its broad
late-stage pipeline and remains committed to delivering medicines for
cardiovascular disease.”   

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards